Arsenic trioxide (As 2 O 3 ) is a highly effective treatment for patients with relapsed acute
promyelocytic leukemia (APL); its role as consolidation treatment for patients in first remission …

Background The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL
tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to …

Purpose: Patients with high-risk myelodysplastic syndrome (MDS) have high mortality from
bone marrow failure or transformation to acute leukemia. Supportive care is standard therapy. …

Background About 65 percent of previously untreated adults with primary acute myeloid
leukemia (AML) enter complete remission when treated with cytarabine and an anthracycline. …

Acute myeloid leukemia (AML) can develop after an antecedent myeloid malignancy (secondary
AML [s-AML]), after leukemogenic therapy (therapy-related AML [t-AML]), or without an …

… Mark, Shelly L. Kerman, and Aurelia Meloni-Ehrig (Grant No. CA08025); State University
of New York Upstate Medical University, Syracuse, NY: Stephen L. Graziano and …

Objective: To determine the most effective, evidence-based approach to the use of platelet
transfusions in patients with cancer. Outcomes: Outcomes of interest included prevention of …

Background A role of microRNAs in cancer has recently been recognized. However, little is
known about the role of microRNAs in acute myeloid leukemia (AML). Methods Using …

Purpose: The impact of azacytidine (Aza C) on the quality of life of 191 patients with
myelodysplastic syndrome was assessed in a phase III Cancer and Leukemia Group B trial (9221). …

Background Elderly patients with primary acute myelogenous leukemia (AML) are less likely
to enter remission than younger adults, in part because of a higher mortality rate related to …